弥漫性大B细胞淋巴瘤 (DLBCL) 治疗的前景：全球研究见解

<!DOCTYPE html> <html lang="zh" xmlns:wb="//open.weibo.com/wb"> <head> <meta charset="utf-8"> <title>弥漫性大B细胞淋巴瘤 (DLBCL) 治疗的前景：全球研究见解 - 美国商业资讯</title> <meta name="viewport" content="width=device-width, initial-scale=1.0"> <meta name="description" content="BOSTON--(美国商业资讯)-- Novotech（诺为泰）是一家专门与生物技术公司合作、加快各个阶段先进新型疗法的开发、可提供全方位服务的国际性临床合同研究组织 (CRO)。近日，诺为泰发布了关于弥漫性大B细胞淋巴瘤(DLBCL) 全球临床试验概况的新见解，进一步巩固了其在肿瘤研究领域的"> <meta name="keywrods" content=""> <meta name="author" content="Business Wire China"> <link href="/css/bootstrap.css" rel="stylesheet"> <link href="/css/main.css?ver=20220804" rel="stylesheet"> <link href="/css/bootstrap-responsive.css" rel="stylesheet"> <script type="text/javascript" src="/js/jquery.min.js"></script> <script type="text/javascript" src="/js/bootstrap.js"></script> <script type="text/javascript" src="/js/main.js"></script>  <script src="//tjs.sjs.sinajs.cn/open/api/js/wb.js" type="text/javascript" charset="utf-8"></script> </head> <body>  <div class="header"> <div class="wrap"> <div class="container"> <div class="full_980 relative">  <div class="top_panel visible-desktop"> <a href="/zh">简体中文</a> | <a href="/hk">繁體中文</a> | <a href="/en">English</a> <div class="globalsite"><select id="globalsite" class="languages"><option value="0">美国商业资讯全球站点</option> <option value="1">Business Wire Global</option><option value="3">UK/Ireland</option><option value="4">Deutschland</option><option value="5">France</option><option value="6">Italy</option><option value="7">Japan</option> </select> </div> </div> <div class="logo"><a href="/zh"><img src="/images/bwlogo_webmain_china.png" alt="美国商业资讯" width="360" height="80"/></a></div> <div class="clear"></div> <div class="navigation"> <ul class="sf-menu"> <li class="current"><a href="/zh">首页</a> </li> <li><a href="/zh/news/index.html">新闻稿中心</a> </li> <li><a href="/zh/events/index.html">会展信息</a> </li> <li><a href="/zh/medias/index.html">媒体合作</a> </li> <li><a href="/zh/about/index.html">美国商业资讯</a> <ul> <li><a href="/zh/about/contact.html">联系我们</a></li> </ul> </li> </ul> <div class="clear"></div>  <div class="search_form visible-desktop"> <form action="/zh/news/search.html" method="get"> <input class="inp_search" name="s" type="text" value="搜索..." title="搜索..." /> <input type="submit" class="search_btn" value=" " /> </form> </div>  </div>  </div> </div> </div> </div>   <div class="page_wrapper"> <div class="wrap"> <div class="container"> <div id="content"> <script src="http://tjs.sjs.sinajs.cn/open/api/js/wb.js?appkey=3616646312" type="text/javascript" charset="utf-8"></script> <script type="text/javascript" src="/js/swfobject.js"></script> <div class="full_980 main_wrap"> <div class="row"> <div class="span9 main_block story"> <p><img src="/files/logos/N/Novotech-TM-Verticle-logo-navy-new-tag.jpg" alt="Novotech"></p> <h2 class="storytitle">弥漫性大B细胞淋巴瘤 (DLBCL) 治疗的前景：全球研究见解</h2> <div class="storytimelang"> <span class="time">2024-11-18 10:14</span> <span class="lang"> <ul> <li><a href="/zh/news/58324.html"><img src="/images/zh_cn.png" alt="zh_cn"></a></li> <li><a href="/hk/news/58324.html"><img src="/images/zh_hant.png" alt="zh_hant"></a></li> <li><a href="/en/news/58324.html"><img src="/images/en.png" alt="en"></a></li> </ul> </span> <div class="clear"></div> </div> <ul class="industry-list"> <li><a href="/zh/industry/health-pharmaceutical.html" class="btn">医药和健康</a></li> </ul> <div class="storycontent"> <p> BOSTON--(美国商业资讯)-- Novotech（诺为泰）是一家专门与生物技术公司合作、加快各个阶段先进新型疗法的开发、可提供全方位服务的国际性临床合同研究组织 (CRO)。近日，诺为泰发布了关于弥<a href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fnovotech-cro.com%2Fcn%2Freports%2Fdiffuse-large-b-cell-lymphoma-global-clinical-trial-landscape-2024%3Futm_source%3DBusinessWire%26utm_medium%3DPress%2BRelease%26utm_campaign%3D2024_Nov_DLBCL_DR_CHS%26utm_id%3D701Oc00000D68MnIAJ&esheet=54150824&newsitemid=20241115418952&lan=zh-CN&anchor=%26%2328459%3B%26%2324615%3B%26%2322823%3BB%26%2332454%3B%26%2332990%3B%26%2328107%3B%26%2324052%3B%26%2330244%3B%28DLBCL%29&index=1&md5=0db8ab5294c9203c85b6962a1ec2fdbe">漫性大B细胞淋巴瘤(DLBCL)</a> 全球临床试验概况的新见解，进一步巩固了其在肿瘤研究领域的重要地位。</p> <p> 本新闻稿包含多媒体。此处查看新闻稿全文： <a href="https://www.businesswire.com/news/home/20241115418952/zh-CN/">https://www.businesswire.com/news/home/20241115418952/zh-CN/</a></p> <p> 弥漫性大B细胞淋巴瘤是非霍奇金淋巴瘤中较常见、较具侵袭性的亚型，其病例在全球病例中占30-40%。弥漫性大B细胞淋巴瘤异质性以生发中心B细胞样 (GCB) 和活化B细胞样 (ABC) 等关键亚型为特征，给治疗带来了重大挑战。诺为泰发布的最新分析报告突出了弥漫性大B细胞淋巴瘤的复杂性，并强调了该侵袭性疾病治疗策略所不断取得的进步。</p> <p> <strong>关于弥漫性大B细胞淋巴瘤临床试验的重要见解</strong></p> <p> 自2019年以来，全球已启动1500多项弥漫性大B细胞淋巴瘤临床试验，凸显了相关研究的强势劲头：</p> <ul> <li> <strong>亚太地区</strong>：临床试验数量占总数的41%，主要受到中国临床研究活动的推动。</li> <li> <strong>北美</strong>：临床试验数量占总数的33%，其中，美国的临床研究数量相对突出。</li> <li> <strong>欧洲</strong>：临床试验数量占总数的19%，侧重于血液肿瘤和实体肿瘤研究。</li> </ul> <p> 研究结果表明了全球致力于改善面向弥漫性大B细胞淋巴瘤患者的疗法。</p> <p> <strong>弥漫性大B细胞淋巴瘤治疗取得的进展</strong></p> <p> 诺为泰发布的报告还强调了弥漫性大B细胞淋巴瘤的治疗所取得的突破。这些突破超越了传统化疗方式，探索了新的治疗方案：</p> <ul> <li> <strong>靶向疗法</strong>：<strong>莫妥珠单抗</strong>和<strong>塞利尼索</strong>的III期临床试验显示了广阔前景，尤其为复发性或难治性弥漫性大B细胞淋巴瘤患者带来了曙光。</li> <li> <strong>免疫疗法</strong>：诺为泰致力于<strong>CAR-T细胞疗法</strong>、<strong>检查点抑制剂</strong>和<strong>双特异性抗体</strong>的开发，这使得对R-CHOP等标准疗法无效的高危弥漫性大B细胞淋巴瘤患者获得了较佳疗效。</li> </ul> <p> 借助基因组测序和分子诊断对弥漫性大B细胞淋巴瘤实施个性化治疗所付出的不懈努力有望产生更精确、更有效的治疗策略。通过与靶向GCB亚型的EZH2抑制剂和靶向ABC亚型的新型药物等创新疗法相结合，这些疗法正在推进实施更具个性化和成效的干预措施。</p> <p> <strong>下载完整报告</strong></p> <p> 请下载诺为泰最新发布的<a href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fnovotech-cro.com%2Fcn%2Freports%2Fdiffuse-large-b-cell-lymphoma-global-clinical-trial-landscape-2024%3Futm_source%3DBusinessWire%26utm_medium%3DPress%2BRelease%26utm_campaign%3D2024_Nov_DLBCL_DR_CHS%26utm_id%3D701Oc00000D68MnIAJ&esheet=54150824&newsitemid=20241115418952&lan=zh-CN&anchor=%26%2324357%3B%26%2328459%3B%26%2324615%3B%26%2322823%3BB%26%2332454%3B%26%2332990%3B%26%2328107%3B%26%2324052%3B%26%2330244%3B%26%2320840%3B%26%2329699%3B%26%2320020%3B%26%2324202%3B%26%2335797%3B%26%2339564%3B%26%2327010%3B%26%2320917%3B%26%2325253%3B%26%2321578%3B&index=2&md5=46ead707e98ad759fbc2b863a621aae6">弥漫性大B细胞淋巴瘤全球临床试验概况报告</a>，了解关于弥漫性大B细胞淋巴瘤临床试验概况（如新兴治疗策略和全球临床试验趋势）的详细分析。</p> <p> 【<a href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fnovotech-cro.com%2Fcn%2Freports%2Fdiffuse-large-b-cell-lymphoma-global-clinical-trial-landscape-2024%3Futm_source%3DBusinessWire%26utm_medium%3DPress%2BRelease%26utm_campaign%3D2024_Nov_DLBCL_DR_CHS%26utm_id%3D701Oc00000D68MnIAJ&esheet=54150824&newsitemid=20241115418952&lan=zh-CN&anchor=%26%2328857%3B%26%2320987%3B%26%2327492%3B%26%2322788%3B%26%2319979%3B%26%2336733%3B%26%2325253%3B%26%2321578%3B&index=3&md5=f9f1d22a5a9d70eb2b37bea45a82e71d">点击此处下载报告</a>】</p> <p> *本文仅作知识分享，不构成任何诊断或治疗建议，如有诊疗需要，请咨询和联系正规医疗机构。</p> <p> 关于诺为泰<a href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fnovotech-cro.com%2Fcn%2Fabout%3Futm_source%3DBusinessWire%26utm_medium%3DPress%2BRelease%26utm_campaign%3D2024_Nov_DLBCL_DR_CHS%26utm_id%3D701Oc00000D68MnIAJ&esheet=54150824&newsitemid=20241115418952&lan=zh-CN&anchor=Novotech-CRO.com&index=4&md5=57919690280a123a6f447a7ec35491c5">Novotech-CRO.com</a></p> <p> <strong>Novotech（诺为泰）成立于1997年，是一家可提供全方位服务的专业生物技术合同研究组织（CRO），致力于加速临床各个阶段创新药物和先进疗法的开发。</strong></p> <p> 诺为泰因其在行业内的突出贡献而备受赞誉，曾荣获多项殊荣，其中包括弗若斯特沙利文2024年全球生物技术CRO奖 (Frost & Sullivan 2024 Global Biotech CRO Award)、2024年临床试验竞技场卓越奖 (Clinical Trials Arena Excellence Awards 2024)、2024年优选雇主 (2024 Employer of Choice)、2024年美国Great Place to Work（卓越职场）认证 (2024 Great Place to Work in the US)、2024年布兰登·霍尔专业能力和技能发展金奖 (2024 Brandon Hall Gold Award)、2023年CRO领导力奖 (CRO Leadership Award 2023)、2023年亚太地区细胞与基因治疗临床试验卓越奖 (Asia Pacific Cell & Gene Therapy Clinical Trials Excellence 2023) 和自2006年以来蝉联亚太地区合同研究组织年度公司奖 (Asia-Pacific Contract Research Organization Company of the Year Award)。</p> <p> 诺为泰是一家包含实验室、Ⅰ期临床中心、药物开发咨询和专业法规服务的临床CRO，拥有超5,000 项临床项目经验，包括Ⅰ期至Ⅳ期临床试验和生物等效性研究。诺为泰目前在全球34个办公地点共拥有3000多名员工，是值得信赖的战略合作伙伴。</p> <p> 要了解更多信息或与专家团队成员交谈，请访问<a href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fnovotech-cro.com%2Fcn%2Ftalk-to-an-expert%3Futm_source%3DBusinessWire%26utm_medium%3DPress%2BRelease%26utm_campaign%3D2024_Nov_DLBCL_DR_CHS%26utm_id%3D701Oc00000D68MnIAJ&esheet=54150824&newsitemid=20241115418952&lan=zh-CN&anchor=www.Novotech-CRO.com&index=5&md5=8c141e0559ae57222fadd638336748e4">www.Novotech-CRO.com</a></p> <p> 在 businesswire.com 上查看源版本新闻稿: <a href="https://www.businesswire.com/news/home/20241115418952/zh-CN/">https://www.businesswire.com/news/home/20241115418952/zh-CN/</a></p> <p> <strong>CONTACT: </strong></p> <p> <strong>媒体联系信息 </strong><br /> <strong>Toyna Chin </strong><br /> <a href="mailto:mediacontact@novotech-cro.com"><strong>mediacontact@novotech-cro.com </strong></a><br /> 美国：+1 415 364 8135</p> <div class="story-image"> <img src="/files/news/54150824-1731896324-1.jpg" alt="弥漫性大B细胞淋巴瘤 (DLBCL)"/> <p class="caption">弥漫性大B细胞淋巴瘤 (DLBCL)</p> </div> </div> <div class="subjects"> <ul class="subject-list"> <li><a href="/zh/subject/products-services.html">产品服务</a></li> </ul> </div>  <div id="ckepop"> <span class="jiathis_txt">分享到：    </span> <a class="jiathis_button_tsina"></a> <a class="jiathis_button_tqq"></a> <a class="jiathis_button_renren"></a> <a class="jiathis_button_kaixin001"></a> <a class="jiathis_button_tsohu"></a> <a class="jiathis_button_t163"></a> <a class="jiathis_button_fb"></a> <a class="jiathis_button_googleplus"></a> <a class="jiathis_button_tifeng"></a> <a class="jiathis_button_thexun"></a> <a class="jiathis_button_cnfol"></a> <a class="jiathis_button_txinhua"></a> <a class="jiathis_button_linkedin"></a> <a href="http://www.jiathis.com/share" class="jiathis jiathis_txt jtico jtico_jiathis" target="_blank"></a> </div> <script type="text/javascript" src="http://v3.jiathis.com/code/jia.js?uid=1344225902068353" charset="utf-8"></script> <div class="clear"></div> <div class="commentbox"> <wb:comments url="auto" border="y" width="auto" skin="blue" appkey="3616646312" ></wb:comments> </div> </div> <div class="span3 sidebar"> <div class="widget"> <h3>美国商业资讯微博</h3> <wb:follow-button uid="2676312451" type="red_2" width="136" height="24" ></wb:follow-button> </div> <div class="widget"> <h3>新闻稿中心</h3> <ul class="industry"> <li><a href="/zh/industry/corporate-social-responsibility">企业社会责任</a></li> <li><a href="/zh/industry/manufacturing">制造业</a></li> <li><a href="/zh/industry/chemical">化工</a></li> <li><a href="/zh/industry/health-pharmaceutical">医药和健康</a></li> <li><a href="/zh/industry/property">建筑和房地产</a></li> <li><a href="/zh/industry/travel">旅游</a></li> <li><a href="/zh/industry/automotive">汽车</a></li> <li><a href="/zh/industry/life-entertainment">生活和娱乐</a></li> <li><a href="/zh/industry/energy-environmental">能源和环境</a></li> <li><a href="/zh/industry/retail">零售</a></li> <li><a href="/zh/industry/transportation">运输和物流</a></li> <li><a href="/zh/industry/business-ecommerce">商务</a></li> <li><a href="/zh/industry/communications-media">通信和传媒</a></li> <li><a href="/zh/industry/metals-mining">金属和矿产</a></li> <li><a href="/zh/industry/finance">金融</a></li> <li><a href="/zh/industry/technology">高科技</a></li> <li><a href="/zh/industry/sports">体育</a></li> <li><a href="/zh/industry/education">教育</a></li> <li><a href="/zh/industry/art-culture">艺术文化</a></li> <li><a href="/zh/industry/legal">法律</a></li> </ul> </div> <div class="widget"> <h3>最新新闻稿</h3> <ul class="story"> <li><span class="time">2024-11-22 16:15</span><br/><a href="/zh/news/58380.html">SIAL Paris 2024：迎来60周年庆的非凡盛会</a></li> <li><span class="time">2024-11-22 15:12</span><br/><a href="/zh/news/58378.html">Rigaku在美国开设生物科学实验室</a></li> <li><span class="time">2024-11-22 14:59</span><br/><a href="/zh/news/58377.html">PUMA发布新播客“绿色旗帜”：让Z世代参与可持续发展</a></li> <li><span class="time">2024-11-22 14:50</span><br/><a href="/zh/news/58376.html">Moody’s收购Numerated Growth Technologies，拓展贷款技术解决方案</a></li> <li><span class="time">2024-11-22 11:17</span><br/><a href="/zh/news/58375.html">Andersen在10个亚太国家和地区推进全球估值业务</a></li> </ul> </div> </div> </div> </div> </div> </div> </div> </div>   <div id="footer" class="hidden-phone"> <div class="wrap"> <div class="container"> <div class="full_980 relative">  <a href="#" id="totop_btn" class="visible-desktop visible-tablet" title="回到顶端"></a>   <div class="footer_top"> <div class="col940"> <div class="row"> <div class="span4"> <h4>上海</h4> <p class="foot_home">上海市江宁路167号新城大厦1502室</p> <p class="foot_phone">+86 21 5239 8905</p> <p class="foot_email"><a href="mailto:sh@businesswirechina.com">sh@businesswirechina.com</a></p> </div> <div class="span4"> <h4>Business Wire Hong Kong</h4> <p class="foot_home">51/F Hopewell Centre, 183 Queen's Road East<br/>Wan Chai, Hong Kong</p> <p class="foot_phone">+852 3602 3091</p> <p class="foot_email"><a href="mailto:hk@businesswire.com">hk@businesswire.com</a></p> </div> <div class="span4"> <h4 style="text-align: center;text-transform:none;">官方微信：Interfax_China</h4> <p style="text-align: center;"><img src="/images/wechat-bwchina.jpg" style="width:160px" alt="官方微信：Interfax_China"/> </p> </div> </div> </div> </div> <div class="footer_bottom"> <div class="fleft"> <div class="copyright">© 2008-2018 Interfax Business Wire Services 版权所有，未经许可不得转载。</div> </div> <div class="clear"></div> </div>  </div> </div> </div> </div> <script type="text/javascript"> var _gaq = _gaq || []; _gaq.push(['_setAccount', 'UA-669196-13']); _gaq.push(['_trackPageview']); (function() { var ga = document.createElement('script'); ga.type = 'text/javascript'; ga.async = true; ga.src = ('https:' == document.location.protocol ? 'https://ssl' : 'http://www') + '.google-analytics.com/ga.js'; var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(ga, s); })(); </script> <script language="javascript"> $(document).ready(function() { $("#globalsite").bind("change",function(){ var links = ['','http://www.businesswire.com','http://www.businesswire.ca/','http://www.businesswire.co.uk/','http://www.businesswire.de/','http://www.businesswire.fr/','http://www.businesswire.it/','http://www.businesswire.jp/']; var val = $(this).val(); var link = links[val]; if(link.length>0) { window.open(link); } }); }); </script> </body> </html>

CINXE.COM

弥漫性大B细胞淋巴瘤 (DLBCL) 治疗的前景：全球研究见解 - 美国商业资讯